Clinical Trials Logo

Rare Cancer clinical trials

View clinical trials related to Rare Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04166006 Recruiting - Clinical trials for Neuroendocrine Tumors

A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

RaC-Ad
Start date: December 12, 2019
Phase: Phase 2
Study type: Interventional

Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head/Neck tumors (H&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).

NCT ID: NCT03740503 Recruiting - Breast Cancer Clinical Trials

Genomic Investigation of Unusual Responders

GENIUS
Start date: November 1, 2013
Phase:
Study type: Observational

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.

NCT ID: NCT02906943 Recruiting - Breast Cancer Clinical Trials

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

OCTANE
Start date: August 2016
Phase:
Study type: Observational

Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease. Biomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment. The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient. Another goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research. The study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.

NCT ID: NCT01517945 Recruiting - Breast Cancer Clinical Trials

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

Start date: January 2012
Phase:
Study type: Observational

The purpose of this study is to test, customize, and personalize a mobile app-based intervention program in order to help rare and breast cancer survivors cope with fears of cancer recurrence.